◆ Market Terminal AILook up a stock

Indivior Pharmaceuticals Inc (INDV)

Healthcare · Drug Manufacturers - Specialty & Generic · Mid-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. Indivior Pharmaceuticals Inc is an average business by our measures, its shares look fairly priced, and its share price has been weak.
Value58
Quality63
Price trend28
Overall53
1021 of 2764rank among the US stocks we score (our core model buys the top 15)
63%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$1.2B
Sales growthchange from the year before+4.3%
Gross marginshare of sales left after the direct cost of what it sells80.2%
Operating marginshare of sales left after running the business21.1%
Net marginshare of sales kept as profit16.9%
Free-cash-flow marginspare cash generated per $100 of sales-7.5%
Return on equityprofit vs. shareholders' accounting valuen/m
Debt / equitydebt vs. shareholders' accounting valuen/m
Interest coverhow many times profit covers interest payments6.9x
Change in share countnegative = the company is buying back its shares-3.8%

Insider trades, last 90 days

1 insider bought $54K on the open market.

Anderson Woodrow DChief Accounting OfficerBoughtAug 51,500 shat $36.28 · $54K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy